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Abstract. Introduction: The positron emission tomogra-
phy (PET) tracers 18F-fluoro-ethyl-L-tyrosine (FET),
18F-fluorocholine (N,N-dimethyl-N-[18F]fluoromethyl-
2-hydroxyethylammonium (FCH]) and 18F-fluoro-2-deox-
yglucose (FDG) are used in the diagnosis of brain
tumours. The aim of this study was threefold: (a) to
assess the uptake of the different tracers in the F98 rat
glioma, (b) to evaluate the impact of blood-brain barrier
(BBB) disruption and microvessel density (MVD) on
tracer uptake and (c) to compare the uptake in the tumours
to that in the radiation injuries (induced by proton
irradiation of healthy rats) of our previous study.
Methods: F98 gliomas were induced in 26 rats. The uptake
of FET, FCH and FDG was measured using autoradiog-
raphy and correlated with histology, disruption of the BBB
and MVD.
Results: The mean FET, FCH and FDG standardised uptake
values (SUVs) in the tumour and the contralateral normal
cortex (in parentheses) were 4.19±0.86 (1.32± 0.26), 2.98±
0.58 (0.51±0.11) and 11.02±3.84 (4.76±1.77) respectively.
MVD was significantly correlated only with FCH uptake.
There was a trend towards a negative correlation between the
degree of BBB disruption and FCH uptake and a trend
towards a positive correlation with FET uptake. The ratio of
the uptake in tumours to that in the radiation injuries was 1.97
(FCH), 2.71 (FET) and 2.37 (FDG).
Conclusion:MVD displayed a significant effect only on FCH
uptake. The degree of BBB disruption seems to affect the
accumulation of FET and FCH, but not FDG. Mean tumour
uptake for all tracers was significantly higher than the
accumulation in radiation injuries.
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Introduction
Positron emission tomography (PET) is a well-established
modality in the evaluation of brain tumour patients.
Twenty-two years ago the first brain tumour images were
acquired with 18F-fluoro-2-deoxyglucose (FDG), which
has become the most widely used tracer in PET imaging
[1]. Although the usefulness of FDG in tumour imaging is
beyond doubt, there are drawbacks. The high physiological
uptake in the brain often renders it difficult to differentiate
tumour from normal brain tissue, a problem which cannot
always be overcome by correlation with structural imaging.
Another problem is the large range of FDG uptake in
different brain tumours, leading to an overlap with the
degree of uptake in benign lesions [2, 3]. Furthermore,
FDG is taken up by tumour cells as well as inflammatory
cells, reducing its specificity in oncological imaging [4, 5].
These limitations led to the development of new
radiotracers such as radiolabelled choline compounds (e.g.
18F-fluorocholine: N,N-dimethyl-N-[18F]fluoromethyl-2-hy-
droxy-ethylammonium [FCH]) or amino acid analogues
like 18F-fluoro-ethyl-L-tyrosine (FET). Both tracers show a
high tumour to background ratio, which facilitates the
detection and delineation of especially low-grade and/or
cortical tumours. They also seem promising candidates for
the differentiation of recurrent brain tumour from radiation
injury [6–8]. Moreover, FET, unlike FCH and FDG, does
not accumulate in inflammatory cells, a feature which
increases the specificity of FET in tumour imaging [9–11].
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FET is an amino acid analogue which is not metabolised
or incorporated into proteins [12]. A specific Na+-inde-
pendent amino acid transport system, the L-system, as well
as the Na+-dependent system B0, +, is responsible for the
high FET accumulation in different tumour cell lines [13,
14]. Wester et al. introduced this tracer to clinical research
[12]. Further studies have demonstrated an increased
uptake of FET in various brain tumours [8, 15–18], but
there are still open questions concerning the main uptake
mechanism(s) of FET in vivo. Besides the L- and B0,+
systems, which are located in the membranes of brain
endothelial cells (L) and tumour cells (L, B0, +), blood-
brain barrier (BBB) disruption, tumour perfusion and the
microvessel density (MVD) could influence tracer accu-
mulation. In this respect, Kracht et al. found a positive
correlation between the microvessel count and the uptake
of [11C]methionine (MET), a radiolabelled amino acid
widely used as a tracer in gliomas [19]. To our knowledge
no data are available on the correlation between the MVD
and FET uptake.
Choline, an important compound of the cell membrane,
is transported into mammalian cells by a low-affinity
sodium-independent transport system and then phosphor-
ylated by choline kinase [20]. In a further step it is
metabolised to phosphatidylcholine, which is incorporated
into the cell membrane. In previous studies the increased
choline uptake in tumour cells was mainly explained by the
upregulation of choline kinase due to an increased demand
of membrane constituents [21–23]. However, Henriksen et
al. postulated a specific choline transport system in tumour
cells as the major mechanism for the clinically important
early uptake of radiolabelled choline derivatives [24].
Initial clinical studies with [11C]choline demonstrated the
diagnostic potential of this substance in different tumours
[25–29]. DeGrado et al. introduced FCH for brain tumour
imaging [30]. The major advantage of 18F-labelled
compounds, especially in clinical use, is the longer
physical half-life of 18F (110 min) compared with 11C
(20 min). This allows several PET examinations with one
production. The tumour uptake pattern of [11C]choline and
18F-substituted choline analogues is very similar [7]. As
mentioned above, tumour uptake seems highly related to
transport and choline kinase activity of the tumour cells
themselves but can also be influenced by the BBB (specific
transport or disruption), tumour perfusion and the MVD.
The aim of this study was threefold: (a) to assess the
uptake of the different tracers in the F98 rat glioma, (b) to
evaluate the impact of BBB disruption and MVD on tracer
uptake and (c) to compare the uptake in the tumours to that
in the radiation injuries of our previous study [31]. In that
project, radiation injuries were induced with 150 or 250 Gy
proton irradiation. Following the development of a
circumscribed lesion, the uptake of FET, FCH or FDG
was measured using autoradiography and correlated with
the histology and the disruption of the BBB.
Materials and methods
Animals
A total of 26 male Fischer 344 rats weighing 250–300 g were used in
this study. The experiments were approved by the local veterinary
authorities of the Canton of Zurich/Switzerland.
Radiopharmaceuticals
FDG was obtained from the commercial FDG production of the
University Hospital Zurich. The production of FET and FCH has
been described in detail elsewhere [31].
Cell culture
The rat glioma cell line F98 was provided by G. Mies (Cologne,
Germany). F98 cells were grown in DMEM containing 4,500 mg/l D-
glucose (GIBCO, Life Technologies, Basel, Switzerland) supple-
mented with 10% FCS, 2 mM N-acetyl-L-alanyl-L-glutamine
(Biochrom AG, Germany) and 20 μg/ml gentamicin (Sigma-Aldrich,
Germany). For injection, cells were harvested by trypsinisation,
washed 3 times with PBS and resuspended at a final concentration of
50 million cells/ml.
Inoculation procedure
Rats were anaesthetised with an intraperitoneal injection of a
ketamine (100 mg/kg; Ketasol 100, Dr. E. Graeub AG, Bern,
Switzerland)/xylazine (10 mg/kg; Xylasol, Dr. E. Graeub AG, Bern,
Switzerland) mixture and placed in a stereotactic frame. We used the
inoculation method of Ambar et al. with minor modifications [32].
After preparation of the inoculation area, a small hole was drilled into
the skull. Then, 1×106 F98 cells in 2 μl were implanted into the left
parietal cortex at a depth of 1 mm ventral to the dura mater using a
10 μl–26 gauge Hamilton syringe (Hamilton, Bonaduz, Switzer-
land). After a short incubation time the syringe was slowly removed
and the hole was closed. The well-being of the animals were then
monitored daily.
Magnetic resonance imaging
Every second rat was examined once with MRI between day 7–14
after inoculation for tumour growth control. Magnetic resonance
imaging (MRI) was performed on a 1.5-T system (GE Signa
EchoSpeed Plus 1.5 T with Excite II, GE Healthcare, WI, USA). To
maximise the signal to noise ratio, animals were positioned in a
dedicated wrist coil. The imaging protocol included the following
sequences: an unenhanced transaxial T1-weighted spin echo (SE)
sequence [repetition time (TR)/echo time (TE)=300 ms/13 ms; slice
thickness 3 mm, without an interslice gap] and a transaxial or coronal
T2-weighted three-dimensional (3D) fast SE sequence (FSE) (TR/T
3,000/128, slice thickness 1.5 mm). In addition, the T1-weighted
sequence was acquired in the transaxial or coronal plane following
intravenous administration of gadopentetate dimeglumine (Gd-
DPTA; Magnevist, Schering AG, Berlin, Germany; 0.1 mmol/kg
body weight) via a tail vein.
674
European Journal of Nuclear Medicine and Molecular Imaging Vol. 33, No. 6, June 2006
Autoradiography with FET, FCH and FDG
After detection of a tumour on MRI scans, autoradiography was
performed (9–23 days after inoculation). Under isoflurane inhalation
anaesthesia, catheters were placed in the right femoral artery to
monitor blood pressure and the femoral vein to allow intravenous
administration of the tracers and Evans Blue, which was injected 1 h
prior to tracer administration. Evans Blue binds to albumin and
therefore acts as an intravascular contrast medium. More information
is given in the next section. According to basic biodistribution
studies, 15 min (FCH [33] and FET [8]) and 45 min (FDG [34]) were
chosen as tracer uptake times. Following injection of 100–150 MBq
of tracer, the animals were sacrificed using an overdose of
pentobarbital. The brain was removed and instantly frozen in cooled
isopentane. For quantification, 10-μm brain slices (100-μm slice
distance) were placed on a phosphor imaging screen together with
14C standards and left for 240 min. Tritium-sensitive screens (Fuji
TR2025) were used as their uncoated, thin, sensitive layer yields
higher resolution 18F autoradiographs than ordinary screens. The data
were scanned (Fuji BAS 1800 II, pixel size 50 μm) and converted to
kBq/cc. For this conversion the 14C standards had previously been
recalibrated using the data of a 4-h exposure of 10-μm slices of a
brain homogenate containing a defined amount of 18F activity.
For quantitative analysis the activities were then decay corrected
to the time of injection. Dividing these values by the amount of
injected activity per gram of body weight yielded standardised
uptake values (SUVs). Regions of interest (ROIs) were subsequently
placed over the area of average tracer uptake in the tumours and over
the contralateral healthy cortex using the software PMOD [35]. The
division of tumour by contralateral cortex SUVs revealed tumour to
normal brain ratios (TBRs).
Morphological characterisation
For morphological analysis the brains were taken and fixed in 4%
formalin/PBS, followed by haematoxylin/eosin (H&E) conventional
stain and GFAP (glial fibrillary acidic protein) immunohistochem-
istry. Briefly, slides were incubated with anti-GFAP antibody
(1:1,000, DAKO Z0334) without pretreatment. Slides were then
developed using a Ventana machine and the iView DAB (DAKO)
development kit.
For histological analysis of the MVD and the BBB leakage,
brains were frozen in isopentane cooled to −50°C. For the
visualisation of Evans Blue, 10-μm thick slices were fixed with
formalin 4% and stained with DAPI (molecular probes, D-1306).
In each animal the Evans Blue distribution was evaluated on one
typical slice through the tumour. For this purpose the sections were
investigated in a fluorescence microscope (Leica MZ16 FA, Leica
Microsystems AG, Wetzlar, Germany) with the following filter
combination: excitation 540–580 nm, emission 610 nm low pass.
The data were stored as an 8 bit intensity image. ROIs were then
placed on the tumour and the contralateral cortex, and the mean of the
ROI was taken as a measure for relative fluorescence intensity. As
was demonstrated in the work by Saria and Lundberg [36], this
intensity is linearly correlated with the absolute density of Evans
blue. The ratio of the fluorescence intensity in tumour and
contralateral cortex was taken as a measure of BBB disruption,
which was then correlated with the SUV of tracer uptake.
The MVD was assessed in 22 rats using the von Willebrandt
factor stain (vWF). Briefly, brain slices were pretreated with protease
1 for 4 min and stained with polyclonal antibody against vWF
(1:1,000, DAKOA00802). The staining was developed using iVIEW
DAB (DAKO). The number of vessels was counted in a totally
visible tumour diameter of one representative section according to
Weidner et al. [37]. For comparison, the counts were then adjusted to
number per 10 microscopic high-power fields (0.1885 mm2 per
HPF).
Statistics
The present tumour data were compared with those regarding
radiation injury from our previous study [31]. The combined data
were analysed using a two-way analysis of variance with type of
lesion (tumour, radiation injury) and type of tracer (FCH, FET, FDG)
as factors. Spearman rank correlation analyses were performed
between tracer uptake in tumour tissue (quantified as SUVand TBR)
and both microvessel density (MVD) and extravasation of Evans
Blue (EB). Owing to the relatively small number of animals, the
calculated p values were not corrected for multiple comparisons.
Fig. 1. The axial MRI scans of
the rat brain clearly depict the
F98 glioma in the left temporo-
parietal cortex. On the T2-
weighted three-dimensional fast
SE sequence the tumour dem-
onstrates increased signal
intensity (a, arrow). On the T1-
weighted SE scan the signal
intensity is decreased (b, arrow)
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Results
Animals
No animal suffered from systemic side-effects during the
period of observation, except for two rats which developed
neurological signs. These animals were immediately
euthanised.
Development of the F98 glioma
Intracerebral lesions were detected on the MRI scans 7–14
days after inoculation. The diameter of the tumour ranged
from 3 to 6 mm. Typical examples of MRI scans are
demonstrated in Fig. 1. The tumour was located within the
cortex of the left temporo-parietal region and extended into
the white matter.
Morphological characterisation
Histological slices of a typical F98 glioma infiltration are
shown in Fig. 2. The glioma cells diffusely infiltrate the
surrounding brain parenchyma. Occasionally, tumour cells
formed round and expanding cell bulks. Atypical mitosis
were often seen.
Disruption of the blood-brain barrier
Typical examples of Evans Blue fluorescent scans are
illustrated in the left panels of Fig. 3. Extravasation of
Evans Blue as an indication of BBB disruption was present
in each case.
Fig. 2. Microscopic images of
F98 glioma cell transplants in
rat brains. a The side of trans-
plantation in the left hemisphere
near the corpus callosum (H&E,
×1.625). b Higher magnification
of the infiltration zone of the
F98 glioma cells (H&E, ×40).
c Tumour microvessel (centre)
filled with erythrocytes (H&E,
×400). d The perivascular infil-
tration of the tumour cells
(H&E, ×400). Cells spread
along microvessels in the
Virchow-Robin perivascular
space. e Immunohistochemi-
cally labelled host astrocytes
and F98 glioma cells (anti-
GFAP, ×100). As in human
glioblastoma, F98 glioma trans-
plants show only occasional
positivity for GFAP.
f Anti-vWF labelled microves-
sels within the F98 glioma
transplant (anti-vWF, ×200)
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Microvessel density
Transplanted tumour cells exhibit a homogeneous tumour
mass with a fine network of small arterioles and capillaries.
A representative section of the tumour mass shows an
evenly distributed microvascular network (Fig. 2f). Sum-
marising, the mean vessel count in the total sample of 22
histologically analysed rats was 179±59 (mean±standard
deviation) per 10 HPFs (0.1885 mm2 per HPF).
Tracer uptake and correlation with the extravasation
of Evans Blue, microvessel density and uptake
in radiation injury
Examples of autoradiographs of each tracer are demon-
strated on the right side of Fig. 3. Each tumour displayed
markedly higher tracer uptake than the surrounding tissue.
The uptake values are summarised in the left part of
Table 1. For comparison the corresponding values in the
radiation injuries of our previous study [31] are presented
on the right of Table 1 and illustrated in Fig. 4. FDG
displayed the highest SUV, followed by FETand FCH. The
tumour/cortex ratio was highest for FCH. In the tumours
the mean SUV was 1.97 (FCH), 2.71 (FET) and 2.37
(FDG) times higher than in the radiation injuries. For FET
there was no overlap of the SUV in the tumour and
radiation injury, while for FCH and FDG the tumour SUV
was in the same range as the uptake in the radiation injury
in only one animal. For the lesion to cortex ratio there was
no overlap at all. The analysis of variance performed on the
SUV data demonstrated significant main effects of lesion
type (F(1,39)=45.71, p<0.001) and type of tracer
(F(2,39)=25.42; p<0.001) as well as a significant interaction
between the two (F(2,39)=8.03; p<0.005). It is important to
Fig. 3. The left side of the figure
(a, c, e) depicts the disruption
of the BBB as demonstrated
by the leakage of Evans
Blue. The uptake of FCH
(b), FET (d) and FDG (f) is
shown on the right
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note that the methodology for the derivation of the SUVs
was the same in the gliomas and the radiation injuries.
The correlation of tracer uptake (SUV, TBR), MVD and
extravasation of Evans Blue (EB) is demonstrated in Fig. 5.
A significant positive correlation was found between
relative uptake of FCH and MVD. The same tracer
demonstrated a trend towards a negative correlation
between uptake and extravasation of Evans Blue. Another
trend towards a relevant correlation was present for FET
SUV and extravasation of Evans Blue.
No correlation was found between MVD and extrava-
sation of Evans Blue (data not shown).
Discussion
The F98 rat glioma model proved to be very reliable.
Because the tumours have similar characteristics to certain
human high-grade brain tumours [38], the results are
relevant for the interpretation of human PET scans. For
instance, the F98 rat glioma has similar growth character-
istics to the glioblastoma multiforme, the most common
human primary brain tumour, as is demonstrated in Fig. 2.
Furthermore, the cell line is syngeneic in inbred Fischer
rats, which leads to a negligible immune response. This is
important because tumour uptake is not confounded by
uptake into activated inflammatory cells.
Tumour uptake of the different tracers
Not unexpectedly, FDG displayed the highest tumour SUV
of all tracers. The lowest SUV was measured with FCH.
Although it must be mentioned that a direct comparison of
our data with human studies is limited by various factors,
such as different acquisition protocols and modalities as
well as interspecies differences, for all tracers the SUVs
and TBRs were in the range of those observed in human
high-grade gliomas [3, 6, 16, 18, 39]. This correspondence
is another indication of the usefulness of the used glioma
model.
The second aim of the study was to evaluate the effect of
BBB disruption and MVD on tracer uptake. This aim was
inspired by another study, where the uptake of [11C]
methionine in 21 glioma patients was reported to correlate
with MVD [19]. In our study no such correlation was found
Table 1. SUVs of F98 gliomas and radiation injury
Tracer Animal F98 glioma Animal Radiation injury
Tumour Tumour/CTX Nec Nec/RTX
FCH 1 3.21 6.42 1 1.38 2.38
FCH 2 2.83 5.90 2 1.43 2.65
FCH 3 3.01 7.34 3 1.43 2.70
FCH 4 1.93 3.64 4 1.12 2.07
FCH 5 4.08 5.59 5 1.25 2.12
FCH 6 3.03 5.41 6 1.99 3.32
FCH 7 2.92 5.73 7 1.92 2.23
FCH 8 3.04 9.50
FCH 9 2.73 4.79
Mean 2.98 6.03 1.50 2.50
SD 0.58 1.65 0.33 0.44
FET 1 3.98 3.24 1 0.90 1.23
FET 2 2.88 2.46 2 1.29 1.08
FET 3 4.60 3.26 3 1.39 0.89
FET 4 4.21 4.13 4 1.82 1.07
FET 5 5.07 2.93 5 1.80 1.42
FET 6 4.91 3.13 6 1.92 1.78
FET 7 3.47 3.15 7 1.52 0.97
FET 8 1.69 1.10
Mean 4.19 3.19 1.54 1.19
SD 0.86 0.50 0.34 0.29
FDG 1 5.21 1.43 1 3.66 0.85
FDG 2 10.68 1.83 2 4.35 1.20
FDG 3 17.03 1.96 3 4.48 1.02
FDG 4 9.22 2.85 4 5.28 1.04
FDG 5 9.67 2.61 5 3.93 0.93
FDG 6 15.91 3.38 6 6.11 1.37
FDG 7 8.99 2.22
FDG 8 11.42 2.71
Mean 11.02 2.37 4.64 1.07
SD 3.84 0.63 0.91 0.19
FCH18 F-N, N-dimethyl-N-[18 F]fluoromethyl-2-hydroxy-ethylam-
monium, FET18 F-fluoro-ethyl-L-tyrosine, FDG18 F-fluoro-2-
deoxyglucose, SUV standardised uptake value, Tumour average
SUV in the area of the F98 glioma, Nec average SUV in the area of
the radiation necrosis, CTX contralateral cortex
Fig. 4. Comparison of tracer uptake in F98 glioma and in radiation
injuries from a previous study. For the presentation the data were
normalised to the mean of the uptake in the radiation injuries. The
data points represent individual animals. The bars are centered on
the mean and represent ±1SD. The numbers signify the mean SUV
of the original data and the coefficient of variation (SD/mean×100)
in percent
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for FET, the amino acid analogue among our investigated
tracers. This result suggests that the increased FET uptake
in the F98 glioma is mainly determined by a mechanism
located in the tumour cells themselves whereas active
transport across the BBB into the interstitial space is
probably not a rate-limiting factor. Very likely candidates
for this mechanism are up-regulated amino acid transport
ers like system L [L amino acid transporter (LAT) 1–3] and
B0,+ in the tumour cell membrane [14]. According to
previous studies, the LAT2 and B0,+ systems seem to be the
main FET transporters in F98 glioma cells [14, 40].
In addition, we found a trend towards a positive
correlation between FET uptake and the extent of BBB
leakage, which almost reached significance. This result is
in line with our previous experiments in radiation injuries
and cryolesions. These experiments demonstrated that a
disruption of the BBB led to considerable leakage of FET
into interstitial space [31].
In contrast to FET, a significant correlation between
tracer uptake and MVD was found for FCH. This finding is
in line with the work by Shinoura et al., which demon-
strated that [11C]choline TBRs in brain tumours increased
with vessel density [41]. In addition, we found a tendency
towards a negative correlation between FCH uptake and
extravasation of Evans Blue (Fig. 5). This indicates that the
choline carriers which transport FCH across the vessel wall
into the interstitial space are a relevant factor in the kinetic
chain determining FCH uptake [6, 42]. A higher degree of
BBB disruption is probably associated with less function of
the choline carriers in the vessel wall, which might explain
the lower FCH uptake with increasing BBB disruption. A
possible passive leakage of FCH across a disrupted BBB
does not seem to compensate for the decreased function of
the choline carriers in tumour vessels. The present study
does not elucidate the importance of the mechanisms
located in the tumour cells for FCH accumulation.
However, there is evidence that a choline-specific transport
system is primarily responsible for the early uptake of
radiolabelled choline analogues in different tumour cell
lines [24]. Further studies should also address the role of
choline kinase on FCH accumulation using a specific
inhibitor like MN58b [43].
For FDG no significant correlation of tracer uptake and
MVD or BBB disruption was found. This is in contrast to
the human study by Aronen et al. [44]. These authors
correlated the FDG uptake in 21 gliomas with microvas-
cular blood volume (TBV) in the tumours measured with
MRI. They reported a relevant positive correlation in 16 of
Fig. 5. Correlations between tracer uptake [standardised uptake value (SUV) and tumour to normal brain ratio (TBR)] and microvessel
density (MVD) and the extravasation of Evans Blue (EB). The r values represent Spearman’s correlation coefficient
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these tumours. The fact that Aronen et al. used different
types of glioma may explain the discrepancy with our
study. It is known that higher grade of malignancy is often
coupled with increased MVD [37, 45]. However, experi-
mental proof is lacking on whether the increased MVD
directly leads to higher tracer uptake. It is well possible that
an altered mechanism in the malignant cells is responsible
for the increased tracer retention and that the higher MVD
is coincidental. In fact, our study with a single cell line
favours this latter possibility for FDG and FET. For FCH,
the MVD seems to play a more direct role in tracer
retention. This may be relevant if the tracer is to be used for
tumour grading. The potential for such grading has been
demonstrated for FDG [1, 46, 47]. Since increased MVD is
associated with higher tumour malignancy and seems also
to be a factor determining FCH uptake, the latter might in
addition be related to tumour malignancy. This possibility
should be tested in further studies. In contrast, FET PET
does not seem to be a reliable diagnostic tool for grading
brain tumours [16, 48–50]. However, this tracer is very
suitable for the differentiation of malignant from benign
lesions [8, 9, 11, 15, 16, 18].
Comparison of tracer uptake in F98 gliomas
and radiation injuries
The differentiation of radiation injury from recurrent
tumour is a relevant clinical problem in brain tumour
patients who have been irradiated. In our previous study we
investigated the uptake of all three tracers in experimen-
tally induced acute radiation injuries in healthy rat brains
[31]. The comparison clearly demonstrated that the uptake
of all used tracers was significantly higher in the F98
gliomas (Table 1, Fig. 4). For SUV or lesion/contralateral
cortex ratios there was no or only minimal overlap between
the tumour and the radiation injury group. The significant
interaction of lesion type and tracer in the analysis of
variance indicates that there is a difference in the ability of
the investigated tracers to distinguish tumour from radia-
tion injury. Visual inspection of Fig. 4 reveals that FET
seems most favourable. However, FCH and FDG also seem
very suitable.
In clinical practice, the situation is more complicated.
FDG has several drawbacks in the differentiation of
radiation injury from recurrent tumour. For instance,
FDG uptake varies over a wide range in different brain
tumours, and some low- and even some high-grade
tumours display the same or lower FDG SUVs than are
measured in acute radiation injuries [3, 39]. Another
problem is the high accumulation of FDG in normal brain
tissue, which often makes it difficult to identify a lesion.
The situation seems more favourable for FET. In
addition to the present study, other publications have
indicated that FET PET holds promise for the differenti-
ation of benign therapy-induced lesions from recurrent
tumour [8, 16]. Gliomas generally display a higher uptake
than benign lesions like radiation injuries.
For FCH the available data on human brain tumours are
still very limited. The only available SUV data were
published by research groups at the Gunma University
School of Medicine, Maebashi, Japan, and the University
of Turku in Helsinki, Finland, both using [11C]choline PET
[3, 51–53]. The SUV was in the range 0.17–4.40 in
different high-grade gliomas and 0.07–3.31 in low-grade
gliomas. For comparison, SUVs in non-neoplastic brain
lesions (n=5) ranged from 0.17 to 1.22, indicating overlap
with the tumours. In contrast, our investigations demon-
strated that FCH is a promising tracer for the differentiation
of tumour from radiation injury.
In summary, the accumulation of FCH, FET and FDG is
highly increased in F98 rat gliomas relative to uptake in
normal brain. Higher MVD led to higher FCH uptake while
it had no effect on the accumulation of FET or FDG. The
degree of BBB disruption seems to influence the
accumulation of FET and FCH, but not that of FDG. For
all tracers, tumour uptake was significantly higher than
the accumulation in radiation injuries, with almost no
overlap between the groups. This is important for the
differentiation of tumour from radiation injuries in clinical
applications.
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